Commonwealth Equity Services’s Aurinia Pharmaceuticals AUPH Stock Holding History

Commonwealth Equity Services’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Buy	92,149 +5,578	+6%	+$89.1K	﹤0.01%	2347
2026 Q1	$1.28M	Buy	86,571 +54,069	+166%	+$790K	﹤0.01%	2400
2025 Q4	$518K	Buy	32,502 +18,868	+138%	+$267K	﹤0.01%	3153
2025 Q3	$151K	Buy	+13,634	New	+$149K	﹤0.01%	4016
2024 Q2	–	Sell	-11,307	Closed	-$57K	–	4047
2024 Q1	$57K	Buy	+11,307	New	+$76.7K	﹤0.01%	3874
2022 Q4	–	Sell	-10,857	Closed	-$81K	–	3712
2022 Q3	$81K	Buy	10,857 +100	+0.9%	+$866	﹤0.01%	3408
2022 Q2	$108K	Buy	10,757 +467	+5%	+$5.22K	﹤0.01%	3352
2022 Q1	$127K	Sell	10,290 -1,947	-16%	-$30.1K	﹤0.01%	3438
2021 Q4	$279K	Buy	12,237 +1,493	+14%	+$35.4K	﹤0.01%	3035
2021 Q3	$237K	Buy	+10,744	New	+$170K	﹤0.01%	3129
2021 Q2	–	Sell	-13,578	Closed	-$176K	–	3528
2021 Q1	$176K	Buy	+13,578	New	+$197K	﹤0.01%	3161

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services's AUPH Position: Q2 2026 in Review

Commonwealth Equity Services increased its Aurinia Pharmaceuticals (AUPH) stake by 6.4% in Q2 2026, buying an estimated $89.1K and bringing the position to 92,149 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #2347.

Commonwealth Equity Services first reported a position in AUPH in Q1 2021 and has held it in 11 quarters since. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Commonwealth Equity Services held 92,149 shares of Aurinia Pharmaceuticals worth $1.56M as of Q2 2026.
Commonwealth Equity Services bought 5,578 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $89.1K.
Aurinia Pharmaceuticals made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q2 2026, its #2347 holding.
Commonwealth Equity Services first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 11 quarters since.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.